DUBLIN–(BUSINESS WIRE)–The “Cell and Gene Therapy Biomanufacturing Market – A Global and Regional Analysis: Focus on Product Type, Application, Usage, End-user, and Region – Analysis and Forecast, 2022-2031” report has been added to ResearchAndMarkets.com’s offering.
The global cell and gene therapy biomanufacturing market was valued at $12.31 billion in 2022 and is anticipated to reach $29.76 billion by 2031, witnessing a CAGR of 10.31% during the forecast period 2022-2031.
Key Companies Profiled
- Becton, Dickinson and Company
- Bio-Rad Laboratories, Inc.
- Bio-Techne Corporation
- Danaher Corporation
- Endress+Hauser Group Services AG (Analytik Jena GmbH)
- General Electric Company (GE Healthcare)
- Getinge AB
- Infors AG
- Lonza Group Ltd
- Merck KGaA
- Miltenyi Biotec B.V. & Co. KG
- PIERRE GUERIN
- Sartorius AG (Sartorius Stedim Biotech S.A.)
- Thermo Fisher Scientific Inc.
- WuXi AppTec
The growth in the global cell and gene therapy biomanufacturing market is expected to be driven by the increased number of approved therapies and growing infrastructure requirements.
In addition, expansion in target indications for cell and gene therapies creates a demand for large-scale biomanufacturing.
Market Lifecycle Stage
The global cell and gene therapy biomanufacturing market is in progressing phase. The cell and gene therapy market is developing rapidly due to its potential to target chronic and rare/orphan diseases that earlier had limited treatment options. Cell and gene therapies available in the market or in the pipeline are the result of years of pioneering research.
Currently, there are more than 25 cell and gene therapies approved by the FDA in the last 10 years. These factors are expected to drive the demand for consumables, equipment, and software solutions required for manufacturing cell and gene therapy, thereby augmenting the growth of the cell and gene therapy biomanufacturing market.
Moreover, manufacturers began to produce application-specific cell and gene therapy equipment in recent years.
Market Segmentation
Segmentation 1: by Product Type
- Consumables
- Equipment
- Software Solutions
Based on product, the consumables segment in the global cell and gene therapy biomanufacturing market dominated in FY2021. The equipment has a shelf life of five to seven years and software solutions also require a one-time investment with yearly maintenance costs. However, consumables are required more frequently and in large quantities for the production of cell and gene therapies.
Segmentation 2: by Usage
- Commercial Stage Manufacturing
- Research Stage Manufacturing
Based on usage, the global cell and gene therapy biomanufacturing market was dominated by the research stage manufacturing segment in FY2021.
Segmentation 3: by Application
- Upstream Processing
- Harvesting
- Downstream Processing
Based on application, the downstream processing segment accounted for the largest share of the global cell and gene therapy biomanufacturing in FY2021.
Segmentation 4: by End User
- Life Science Companies
- Contract Research Organizations (CROs)
- Contract Manufacturing Organizations (CMOs)
- Cell Banks
Based on end user, the global cell and gene therapy biomanufacturing market is dominated by the life sciences companies segment in FY2021.
Segmentation 5: by Region
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa
In 2021, the North America cell and gene therapy biomanufacturing market dominated the global market with a 44.70% market share, and it is expected to hold its dominance throughout the forecast period 2022-2031. However, the Asia-Pacific (APAC) region, constituting several emerging economies, is expected to register the highest CAGR of 17.88% during the forecast period 2022-2031.
Recent Developments in the Global Cell and Gene Therapy Biomanufacturing Market
- In January 2023, Sartorius AG collaborated with Roosterbio Inc. to advance its downstream purification processes for the development of exosomes.
- In February 2022, Sartorius AG completed the acquisition of Novasep’s chromatography division to complement its own product portfolio.
- In August 2022, Merck KGaA launched VirusExpress 293 Adeno-Associated Virus (AAV) Production Platform to speed up the development of cell and gene therapies.
- In June 2022, Lonza Group AG and Adva Biotechnology Ltd. entered into a license agreement that provides the latter access to the former’s core intellectual property enabling the expansion of automated bioreactors worldwide.
- In June 2022, Becton, Dickinson and Company launched FACSDiscover S8 Cell Sorter featuring CellView Image Technology.
- In January 2023, Bio-Techne Corporation launched RNAscope plus assay to advance its gene therapy development.
- In September 2021, Thermo Fisher Scientific Inc. launched the integrated Gibco AAV-MAX Helper Free AAV Production System for AAV vector production.
Demand – Drivers and Limitations
The following are the demand drivers for the global cell and gene therapy biomanufacturing market:
- Increasing Number of Approved Therapies and Growing Infrastructure Requirements Creating an Upsurge Demand for Cell and Gene Therapy Biomanufacturing Products
- Expansion in Target Indications for Cell and Gene Therapies Creating a Demand for Large-Scale Biomanufacturing
- Entry of New Market Participants in Cell and Gene Therapies Driving the Demand for Biomanufacturing Facilities and Equipment
- Increasing Investments and Fundings in Cell and Gene Therapy Fuelling the Growth of Cell and Gene Therapy Biomanufacturing
The market is expected to face some limitations due to the following challenges:
- High Set-Up Cost of Biomanufacturing Facilities
For more information about this report visit https://www.researchandmarkets.com/r/db9nm0
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900